Abstract library

8 results for "Price".
#1907 Pancreatic Neuroendocrine Tumors in MEN1 Disease: A Monocentrice Longitudinal and Prognostic Study
Introduction: In MEN1+ patients (MEN+), pNETs are considered to be high risk for multiple, malignant and aggressive tumors.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: md Sabrina Chiloiro
Keywords: pNETs, MEN, prognosis
#702 Observational Study of Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors in Argentina: Results from the Large Database of a Multidisciplinary Group. Clinical Multicenter Study
Introduction: Neuroendocrine tumors (NETs) consist of a spectrum of malignancies that can arise from neuroendocrine cells throughout the body.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Juan Manuel O'Connor
#715 Neuroendocrine Tumors of the Rectum: Experience in Argentina
Introduction: Neuroendocrine tumors (NETs) of the rectum have been increasing in incidence. They are approximately 18% the all NETs and 27% of all gastrointestinal NETs. Rectal NETs are usually small and are often found incidentally during endoscopy. Patients (pts) with local disease have a favorable prognosis of a 5-year survival rate of 88-91%. Optimal treatment of NETs of the rectum has been widely debated.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Claudia Bestani
Keywords: rectal NETs
#938 Clinical Characteristics of 144 patients (pts) Included in a Multidisciplinary Group, with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) G2 (WHO 2010). Grupo Argentum.
Introduction: Neuroendocrine tumors (NETs) G2 of the digestive tract are a heterogeneous group of tumors. Several treatment options including chemotherapy and target therapy are used, but there is a lack of prospective trials assessing the role of predictive factors in this population.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD Juan Manuel O'Connor
#1073 The Clinical Oncology Society of Australia (COSA) SIGNETURe Neuroendocrine Tumor (NET) Registry of Australia: First Report of Patient Characteristics and Patterns of Care
Introduction: NETs remain a relatively rare malignancy. Clinical trials are often hindered by the limited number of patients available and thus registries provide important information about patterns of care and patient outcomes.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: A/Prof Timothy Price
Keywords: Registry
#1825 The Effect of PRRT on Health-Related Quality of Life in NET Patients: A Prospective Study
Introduction: Neuroendocrine tumour (NET) patients experience poor health-related quality of life (HRQOL). Peptide receptor radionuclide therapy (PRRT) is a promising treatment option although its impact on HRQOL is not well understood.
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Dainik Patel
#984 Superior Mesenteric Vein Stenting for Management of Complications of Mesenteric Desmoplasia in Midgut Neuroendocrine Tumors
Introduction: Mesenteric fibrosis is a cause of morbidity and mortality in patients with midgut neuroendocrine tumors (mNETs). It may cause occlusion of the superior mesenteric vein (SMV), which can be associated with development ascites and mesenteric and small bowel varices (SBVs) leading to occult gastrointestinal (GI) bleeding.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr Keval B Naik
#1901 Portal Hypertension-Related Digestive Hemorrhage in Patients with Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (pNET) can cause portal hypertension (PHT)
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: Nelly Muller